Essential Thrombocythemia: What Researchers Need to Know

Photo Credit: CDC/ Hsi Liu, Ph.D., MBA, James Gathany

Essential Thrombocythemia (ET) represents a fascinating paradox in hematological disease research. Despite being characterized by marked thrombocytosis — platelet counts frequently exceeding 1,000 × 10⁹/L — many patients remain asymptomatic for years or decades. Yet this apparent benignity belies significant risks: thrombotic and hemorrhagic complications, disease transformation to more aggressive myeloproliferative neoplasms, and substantial impacts on quality of life from constitutional symptoms. For researchers investigating ET, understanding this heterogeneous condition requires navigating complex molecular genetics, clinical phenotypes, and evolving therapeutic landscapes.

High-impact ET research depends on access to well-characterized biospecimens paired with clinical and molecular context — including mutation status, variant allele frequency (VAF), and (when available) co-mutations and longitudinal natural history data. From study design to receipt of samples, rigorous sample handling and annotation standards are essential for reproducible findings and meaningful translation.

Defining Essential Thrombocythemia: A BCR-ABL-Negative MPN

Essential Thrombocythemia belongs to the group of BCR-ABL-negative myeloproliferative neoplasms (MPNs), alongside polycythemia vera and primary myelofibrosis. These conditions share a common origin in clonal hematopoietic stem cell disorders but manifest distinct clinical phenotypes based on their predominant cellular lineage involvement.¹

The 2016 World Health Organization (WHO) diagnostic criteria for ET require meeting four major criteria or the first three major criteria plus the minor criterion:²

Major Criteria

1. Sustained platelet count ≥450 × 10⁹/L
2. Bone marrow biopsy showing proliferation mainly of the megakaryocyte lineage with increased numbers of enlarged, mature megakaryocytes with hyperlobulated nuclei
3. Not meeting WHO criteria for other myeloid neoplasms (BCR-ABL1-positive CML, polycythemia vera, primary myelofibrosis, myelodysplastic syndromes)
4. Presence of JAK2, CALR, or MPL mutation

Minor Criterion

• Presence of a clonal marker or absence of evidence for reactive thrombocytosis

This diagnostic framework emphasizes the importance of molecular testing, which has revolutionized ET classification and prognostication.

The Molecular Landscape: Driver Mutations Define Phenotype

Approximately 90% of ET patients harbor a driver mutation in one of three genes: JAK2, CALR, or MPL. The specific mutation profoundly influences clinical phenotype, thrombotic risk, and natural history patterns.³

JAK2 V617F: The Most Common Driver

Present in approximately 55% of ET cases, the JAK2 V617F mutation causes constitutive activation of JAK-STAT signaling pathways. This mutation is not specific to ET — it’s also found in polycythemia vera and primary myelofibrosis — highlighting the importance of integrating molecular and clinical data for accurate diagnosis.

JAK2-mutated ET characteristics:

• Higher risk of thrombotic complications (arterial more than venous)
• Older age at diagnosis
• Higher hemoglobin levels
• Lower platelet counts compared with CALR-mutated ET
• Increased risk of transformation to polycythemia vera⁴

For biospecimen research, JAK2 mutation status should be documented using validated molecular assays (typically allele-specific PCR or next-generation sequencing). Variant allele frequency (VAF) provides additional prognostic information, with higher VAF generally correlating with more pronounced phenotype.

CALR Mutations: The Recently Discovered Driver

Calreticulin (CALR) mutations, discovered in 2013, account for approximately 25–30% of ET cases. These insertions or deletions in exon 9 create a novel C-terminus that drives oncogenesis through mechanisms distinct from JAK2 activation.⁵

CALR-mutated ET characteristics:

• Younger age at diagnosis
• Higher platelet counts (often >1,000 × 10⁹/L)
• Lower risk of thrombosis compared with JAK2-mutated ET
• Better overall survival
• Male predominance
• Lower risk of transformation⁶

Two major CALR mutation subtypes (Type 1 and Type 2) show differing prognostic implications, with Type 1 generally associated with better outcomes. Biospecimen collections should ideally document the specific CALR variant when known, not just “CALR-positive” status.

MPL Mutations: The Rarest Driver

MPL mutations, affecting the thrombopoietin receptor gene, occur in approximately 3–5% of ET cases. W515L and W515K mutations in exon 10 are most common, causing receptor activation and megakaryocyte proliferation.⁷

MPL-mutated ET characteristics:

• Older age at diagnosis
• Higher risk of anemia
• Bone marrow fibrosis more common
• Intermediate thrombotic risk
• May show more pronounced constitutional symptoms

Triple-Negative ET: The 10% Mystery

Approximately 10% of ET cases lack JAK2, CALR, or MPL mutations (“triple-negative” ET). These cases require particularly careful evaluation to exclude reactive thrombocytosis and other myeloid neoplasms. Some triple-negative cases harbor uncommon mutations detectable by comprehensive next-generation sequencing panels.⁸

Research into triple-negative ET biospecimens may reveal novel pathogenic mechanisms and identify additional driver mutations, making these samples particularly valuable for discovery-focused investigations.

Risk Stratification: Predicting Who Will Have Complications

Not all ET patients face equal risks. Thrombotic complications — the primary concern in ET management — occur in a minority of patients but carry substantial morbidity and mortality. Risk stratification systems classify patients to guide treatment intensity.

Traditional Risk Factors

The conventional approach stratifies patients based on:

• Age: >60 years significantly increases risk
• Thrombosis history: prior thrombotic event is the strongest predictor of recurrence
• Cardiovascular risk factors: hypertension, diabetes, hyperlipidemia, smoking
• Extreme thrombocytosis: platelets >1,500 × 10⁹/L may paradoxically increase bleeding risk

Risk categories:

• Low risk: age ≤60 years, no thrombosis history, no cardiovascular risk factors
• High risk: age >60 years or thrombosis history

This binary classification guides cytoreductive therapy decisions, with high-risk patients typically receiving hydroxyurea or other platelet-lowering agents, while low-risk patients may be managed with aspirin alone.⁹

Mutation-Based Risk Refinement

Emerging evidence suggests that driver mutation status should inform risk assessment:

• JAK2-mutated patients: higher baseline thrombotic risk; may benefit from earlier intervention; aspirin therapy particularly important
• CALR-mutated patients: lower thrombotic risk despite often higher platelet counts; may tolerate conservative management in low-risk settings
• MPL-mutated patients: intermediate risk profile; may require closer monitoring for progression

For biospecimen research investigating thrombotic mechanisms or therapeutic response, stratifying samples by mutation status is essential for identifying genotype-specific biology and developing precision medicine approaches.

Current and Emerging Biomarkers

Beyond driver mutations, researchers are exploring additional biomarkers to enhance ET diagnosis, prognostication, and treatment monitoring.

Inflammatory Cytokines

ET patients show elevated levels of inflammatory cytokines including IL-6, IL-8, and TNF-α. These markers correlate with constitutional symptoms (fatigue, night sweats, pruritus) and may predict disease progression. Specimens suitable for cytokine profiling often include plasma and serum, enabling investigation of inflammatory pathways in MPN pathogenesis.¹⁰

Clonal Hematopoiesis Markers

Beyond driver mutations, acquired mutations in genes associated with clonal hematopoiesis (TET2, ASXL1, DNMT3A) occur in 30–40% of ET patients. These additional mutations impact prognosis, with certain combinations (e.g., JAK2 + ASXL1) associated with higher transformation risk and shorter survival.¹¹

Transcriptomic Signatures

Recent work has identified gene expression signatures that differentiate ET from reactive thrombocytosis and predict disease progression. One study identified biomarkers that forecast transformation to myelofibrosis or acute leukemia using differential gene expression analysis and machine learning approaches.¹²

These emerging biomarkers require validation in independent cohorts with long-term follow-up — work that depends on access to well-annotated biospecimens paired with comprehensive genomic annotation and natural history documentation.

Treatment-Related Complications

Historical use of certain cytoreductive agents increased leukemic transformation risk. While modern therapies like hydroxyurea appear safer, long-term data continue to accrue. Specimens from patients with well-documented treatment histories enable pharmacovigilance studies and investigation of treatment-related mutagenesis.

Therapeutic Landscape: From Cytoreduction to Targeted Agents

Current ET management centers on thrombotic risk reduction through platelet lowering in high-risk patients, with low-dose aspirin playing a central role across risk categories.

First-Line Cytoreductive Therapy

Hydroxyurea remains the standard first-line cytoreductive agent for high-risk ET. It effectively lowers platelet counts, reduces thrombotic risk, and is generally well-tolerated; however, a subset of patients develop resistance or intolerance.¹³

Anagrelide specifically targets megakaryopoiesis and platelet production. It is often used as second-line therapy or in younger patients when long-term hydroxyurea considerations influence decision-making.

Interferons (particularly pegylated interferon-α) show promise in inducing molecular responses (reducing or eliminating mutant allele burden) in some patients. They are increasingly used in younger patients, during pregnancy, and in patients seeking disease-modifying rather than purely symptom-controlling approaches.

Emerging Targeted Therapies

JAK inhibitors and other targeted strategies are under investigation in ET, particularly for symptom control, patients with inadequate response to conventional therapy, or biologically defined subgroups. Research supporting these advances requires biospecimens that capture baseline biology, on-treatment changes, and resistance mechanisms — often necessitating longitudinal collections in clinical trial or real-world settings.

Biospecimen Requirements for ET Research

High-quality Essential Thrombocythemia research depends on specimens that capture the molecular and phenotypic heterogeneity of this condition.

Essential Clinical Annotation

Baseline characteristics:

• Confirmed diagnosis meeting WHO 2016 criteria
• Complete blood counts (platelet count, hemoglobin, white blood cell count)
• Bone marrow biopsy results when available
• Driver mutation status (JAK2 V617F with allele burden/VAF; specific CALR variant; MPL mutation type)
• Additional mutations from extended molecular panels when available
• Spleen size by imaging
• Symptom burden scores (when captured)

Risk stratification data:

• Age at diagnosis
• Prior thrombotic events (arterial vs venous, location, timing)
• Cardiovascular risk factors
• Current risk category assignment

Treatment history:

• Current and prior therapies (hydroxyurea, anagrelide, interferon, JAK inhibitors, aspirin)
• Best response achieved on each therapy
• Reason for therapy change when applicable
• Adverse events experienced

Natural history documentation:

• Duration of follow-up
• Thrombotic or hemorrhagic events during follow-up
• Disease transformation (post-ET MF, PV, acute leukemia) if occurred
• Current disease status

Sample Types and Processing

Different ET research applications require specific sample types:

• Whole blood (EDTA): DNA extraction and mutation analysis; CBC correlation; flow cytometry studies of cellular populations using human whole blood
• Plasma: cytokine profiling; biomarker discovery; proteomics using human plasma (and for assay development/harmonization, bulk plasma)
• PBMCs: single-cell sequencing to define clonal architecture; functional signaling studies; ex vivo drug sensitivity testing using human PBMCs
• Serum: inflammatory marker quantification; metabolomics using human serum

For studies that require high-yield leukocyte inputs for standardized workflows (e.g., immune profiling method development, ex vivo functional assays at scale), human leukopak collections can be used to support robust downstream analyses, and certain programs may require GMP leukopak depending on protocol needs.

At SanguineBio, our hematological disease biospecimens include ET samples with documented mutation status, comprehensive clinical annotation, and options for matched specimen sets from the same patient across multiple timepoints — supporting longitudinal investigations into natural history and treatment response.

Research Priorities and Opportunities

Several key questions in ET research remain incompletely answered, representing opportunities for biospecimen-based investigation:

Why Do Some Patients Transform and Others Don’t?

Despite sharing driver mutations, ET patients show markedly different transformation risks. Identifying biomarkers that predict progression could enable risk-adapted monitoring and potentially preventive interventions.

Can We Achieve Molecular Remissions?

Interferons can reduce or eliminate detectable mutant clones in some patients. Understanding who responds, the durability of responses, and the clinical significance of molecular remission requires well-annotated specimens from interferon-treated cohorts.

What Drives Constitutional Symptoms?

Fatigue, pruritus, night sweats, and other symptoms significantly impact quality of life but often correlate weakly with platelet count alone. Inflammatory cytokines, metabolic alterations, and other mechanisms may drive symptoms, offering potential therapeutic targets.

How Can We Better Risk-Stratify for Thrombosis?

Current risk models remain imperfect. Novel biomarkers — potentially incorporating inflammatory profiles, platelet functional measures, and genomic co-mutation patterns — may enhance risk prediction and guide more personalized therapy decisions.

Conclusion

Essential Thrombocythemia exemplifies the complexity of modern hematological disease research. What once appeared to be a single entity defined by elevated platelet counts is now recognized as molecularly and phenotypically heterogeneous, with treatment responses and outcomes varying by driver mutation, additional genomic alterations, and patient-specific factors.

This heterogeneity creates both challenges and opportunities for researchers. Studies must account for molecular subgroups, often requiring larger sample sizes or focused cohorts. However, this same heterogeneity offers opportunities to identify genotype-specific vulnerabilities and develop precision medicine approaches.

Success in ET research depends fundamentally on access to well-characterized biospecimens with comprehensive annotation covering confirmed diagnosis, mutation status (including VAF and co-mutations), detailed treatment history, and longitudinal natural history data. By partnering with biospecimen providers who understand these requirements and maintain rigorous quality standards from study design to receipt of samples, researchers can ensure their investigations build on the solid foundation needed for reproducible, clinically meaningful discoveries.

---

References (AMA Style)

1. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(4):697-723. doi:10.1002/ajh.27187
2. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. doi:10.1182/blood-2016-03-643544
3. Tefferi A, Pardanani A. Essential thrombocythemia. N Engl J Med. 2019;381(22):2135-2144. doi:10.1056/NEJMcp1910472
4. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128-5133. doi:10.1182/blood-2012-07-444067
5. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390. doi:10.1056/NEJMoa1311347
6. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552-1555. doi:10.1182/blood-2013-11-538983
7. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270. doi:10.1371/journal.pmed.0030270
8. Cabagnols X, Favale F, Pasquier F, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016;127(3):333-342. doi:10.1182/blood-2015-07-661983
9. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770. doi:10.1200/JCO.2010.31.8436
10. Pourcelot E, Trocme C, Mondet J, et al. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42(5):360-368. doi:10.1016/j.exphem.2014.01.006
11. Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1(1):21-30. doi:10.1182/bloodadvances.2016000216
12. Rampal RK, Mascarenhas JO, Kosiorek HE, et al. Identification of biomarkers to predict disease progression via machine learning in myeloproliferative neoplasms. Blood. 2024;146(Suppl 1):5526. doi:10.1182/blood-2024-210861
13. Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, et al. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016;172(5):786-793. doi:10.1111/bjh.13886